Management of thyrotoxicosis and pregnancy: Review of the current literature and an update of the care pathway - 22/07/22
Abstract |
Pregnancy can be complicated by hyperthyroidism or thyrotoxicosis. Diagnosis is founded on an increase in free thyroid hormones and low TSH. The most frequent etiologies are Graves’ disease, an autoimmune disease linked to stimulatory anti-TSH receptor antibodies, and non-autoimmune gestational hyperthyroidism linked to the TSH-like activity of the chorionic growth hormone (hCG). During pregnancy, thyrotoxicosis can entail maternal, obstetrical and fetal or neonatal complications. Graves’ hyperthyroidism may be responsible for fetal and neonatal hyperthyroidism due to placental transfer of stimulatory anti-TSH receptor antibodies. During pregnancy, treatment of thyrotoxicosis must restore normal thyroid function in the mother without affecting fetal thyroid function. The recent reassessment of the prevalence of teratogenic effects in children of women treated with antithyroid drugs in the first weeks of gestation should orient the care pathway before and during pregnancy for women of child-bearing age with hyperthyroidism linked to Graves’ disease.
El texto completo de este artículo está disponible en PDF.Keywords : Pregnancy, Thyrotoxicosis, Hyperthyroidism, Graves’ disease, Antithyroid drugs, Teratogenic side effects
Esquema
Vol 83 - N° 4
P. 226-231 - août 2022 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.